Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
Conditions
Interventions
KarXT
KarX-EC
+1 more
Locations
55
United States
Local Institution - 0062
Phoenix, Arizona, United States
Local Institution - 0001
Bentonville, Arkansas, United States
Local Institution - 0013
Glendale, California, United States
Local Institution - 0117
Los Angeles, California, United States
Local Institution - 0126
Orange, California, United States
Local Institution - 0115
San Juan Capistrano, California, United States
Start Date
September 11, 2026
Primary Completion Date
August 4, 2029
Completion Date
August 4, 2029
Last Updated
April 2, 2026
NCT05555615
NCT04258839
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions